Table 2.
Associations between markers and response to sorafenib
| |
Mean +/- STD |
|
|
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| Marker | Responders | Non-responders | Delta | t-statistic | p-value | ||||
|
MVA |
10.3 |
+/- |
9.7 |
5.6 |
+/- |
4.2 |
4.7 |
2.847 |
0.0055 |
| VEGF |
33.4 |
+/- |
11.2 |
38 |
+/- |
10.9 |
-4.6 |
-1.548 |
0.125 |
| VEGF-R1 |
32.4 |
+/- |
7.6 |
33 |
+/- |
8.2 |
-0.6 |
-0.288 |
0.7739 |
| VEGF-R2 |
31.4 |
+/- |
8.3 |
33.4 |
+/- |
8.0 |
-2 |
-0.929 |
0.3554 |
| VEGF-R3 |
48.3 |
+/- |
13.3 |
50.9 |
+/- |
10.2 |
-2.6 |
-0.879 |
0.3817 |
| c-RAF |
35.1 |
+/- |
14.9 |
34.4 |
+/- |
13.5 |
0.7 |
-0.177 |
0.8601 |
| B-RAF |
39.5 |
+/- |
12.8 |
42 |
+/- |
14.1 |
-2.5 |
-0.707 |
0.4813 |
| c-Kit |
44.0 |
+/- |
12.8 |
43.8 |
+/- |
12.4 |
0.2 |
-0.047 |
0.9629 |
| PDGFR-β | 37.5 | +/- | 14.9 | 33.6 | +/- | 9.5 | 3.9 | -1.321 | 0.1897 |